Journal article

Choice and duration of antifungal prophylaxis and treatment in high-risk haematology patients

Julien Coussement, Julian Lindsay, Benjamin W Teh, Monica Slavin

CURRENT OPINION IN INFECTIOUS DISEASES | LIPPINCOTT WILLIAMS & WILKINS | Published : 2021

Abstract

PURPOSE OF REVIEW: This review aims to summarize available guidelines as well as the emerging evidence for the prevention and treatment of invasive fungal diseases in high-risk haematology patients. RECENT FINDINGS: Primary mould-active prophylaxis is the strategy used in many centres to manage the risk of invasive fungal disease in high-risk haematology patients, and posaconazole remains the antifungal of choice for most of these patients. Data on the use of other antifungals for primary prophylaxis, including isavuconazole, are limited. There is considerable interest in identifying a strategy that would limit the use of mould-active agents to the patients who are the most likely to benefit..

View full abstract

Grants

Funding Acknowledgements

J.L. is supported by a Leukaemia Foundation (LF) and Haematology Society of Australia and New Zealand (HSANZ) New Investigator Scholarship. B.W.T. is supported by the Australian Government NHRMC early career fellowship and the Medical Research Future Fund Investigator Fellowship. M.S. acknowledges National Health and Medical Research Council (Australian Government) funding.